Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2776
Source ID: NCT00943501
Associated Drug: Liraglutide
Title: Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide|DRUG: placebo|DRUG: liraglutide|DRUG: placebo
Outcome Measures: Primary: Number and type of adverse events, up to 8 weeks | Secondary: Pharmacokinetics: Area under the plasma concentration vs. time curve, within dosing interval|Pharmacodynamics: Fasting Plasma Glucose (FPG) and insulin, throughout study duration (pre-, during and post-treatment)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: CHILD
Phases: PHASE1
Enrollment: 21
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2009-11
Completion Date: 2011-09
Results First Posted:
Last Update Posted: 2017-01-26
Locations: Novo Nordisk Investigational Site, Cypress, California, 90630, United States|Novo Nordisk Investigational Site, Los Angeles, California, 90036, United States|Novo Nordisk Investigational Site, Los Angeles, California, 90048-1869, United States|Novo Nordisk Investigational Site, Aurora, Colorado, 80045, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, 52242, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, 40202, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, 64108-4619, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, 45229, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, 44106, United States|Novo Nordisk Investigational Site, Toledo, Ohio, 43606, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, 19104, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, 15224, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, 38103-2800, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75235, United States|Novo Nordisk Investigational Site, Brussels, 1090, Belgium|Novo Nordisk Investigational Site, Ljubljana, 1525, Slovenia|Novo Nordisk Investigational Site, Birmingham, B4 6NH, United Kingdom|Novo Nordisk Investigational Site, Manchester, M13 9WL, United Kingdom|Novo Nordisk Investigational Site, Nottingham, NG7 2UH, United Kingdom|Novo Nordisk Investigational Site, Sheffield, S102TH, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00943501

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress